v3.26.1
Disaggregated Revenues (Tables)
 6 Months Ended
Jun. 30, 2026
Disaggregation of Revenue [Abstract]  
Schedule of Disaggregation of Revenue by Nature
The following table provides information regarding total revenues (dollars in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
(unaudited)(unaudited)
Net product sales
Qelbree$89,239 $77,547 $167,082 $142,292 
GOCOVRI37,530 36,660 72,770 67,349 
ONAPGO13,546 1,604 21,921 1,604 
Trokendi XR8,411 11,193 17,890 23,994 
Oxtellar XR8,782 11,637 16,204 21,835 
APOKYN6,323 12,820 14,051 27,796 
Other(a)
1,882 6,534 6,548 15,113 
Total net product sales165,713 157,995 316,466 299,983 
Collaboration revenue (ZURZUVAE)(b)
35,350 — 62,993 — 
Royalty, licensing, and other revenues17,995 7,458 47,304 15,294 
Total revenues$219,058 $165,453 $426,763 $315,277 
___________________________________________
(a) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
(b) Includes the Company's proportionate share of net sales of ZURZUVAE.